MediBeacon's Kidney Function Monitor Clears EU Regulatory Hurdle
Event summary
- MediBeacon's TGFR Monitor and Reusable Sensor received CE Mark under EU MDR 2017/745 on March 31, 2026.
- The certification covers two Class IIa devices, enabling European clinical trials for the TGFR System.
- Lumitrace (relmapirazin) injection, part of the TGFR System, is approved in the U.S. and China but pending in the EU.
- MediBeacon holds over 55 U.S. patents and 250 global patents for its technology.
The big picture
MediBeacon's CE Mark approval positions its TGFR System for broader European adoption, complementing existing approvals in the U.S. and China. The transdermal GFR monitoring technology addresses a critical need for accurate, point-of-care kidney function assessment, potentially disrupting traditional testing methods. INNOVATE Corp.'s investment in MediBeacon aligns with its life sciences portfolio strategy, targeting high-growth medical technology sectors.
What we're watching
- Regulatory Expansion
- Whether MediBeacon can secure EU approval for Lumitrace injection to complete the TGFR System's European market entry.
- Clinical Adoption
- The pace at which European hospitals integrate transdermal GFR monitoring into clinical research and practice.
- Competitive Positioning
- How MediBeacon's patent portfolio and CE Mark differentiation will impact market share against existing kidney function testing methods.
Related topics